antifolate drug

antifolate drug

see folic acid antagonist.
References in periodicals archive ?
The pyrimethamine (5- (4-chlorophenyl)-6-ethyl- 24-pyrimidinediamine) is a well reported antifolate drug which has been utilized against malaria to target DHFR protein.
The antifolate drug pemetrexed proved effective in patients with adenocarcinoma but not patients with squamous cell carcinoma.
In a pharmacogenetic context, inheritance of an MTHFR 677T-1298A haplotype and an MTHFDI 1958A allele was associated with a lower probability of event-free survival in children treated with the antifolate drug methotrexate for acute lymphoblastic leukemia, particularly when in combination with the thymidylate synthase triple repeat associated with increased thymidylate synthase concentrations (24).
The synthesis of novel nucleoside transport inhibitors will allow for the antifolate drug effectiveness to be maximized through in vitro and eventually in vivo studies.
Shih contributed to the successful antifolate drug discovery program that has led to the development of ALIMTA([R]), a blockbuster anticancer agent approved by various regulatory agencies around the globe for the treatment of mesothelioma and non-small cell lung cancer.
Methotrexate (MTX) is an antifolate drug that inhibits dihydrofolate reductase, thereby depleting the cells of reduced folates, including 5-methyltetrahydrofolate (5).
Talvesta is a novel nonpolyglutamable antifolate drug which targets DHFR under development for the treatment of various types of cancers.
Talvesta is a novel antifolate drug candidate under development for treatment of various types of tumors.
Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension.
Talotrexin (PT-523) is a novel antifolate drug candidate under development for treatment of various types of tumors.
Talotrexin, a novel nonpolyglutamatable antifolate drug, is currently being evaluated in a Phase I/II multicenter clinical trial in patients with relapsed or refractory ALL.
Co-trimoxazole, the antifolate drug combination of trimethoprim and sulfamethoxazole, is the drug of choice for the prophylaxis and treatment of Pneumocystis carinii pneumonia (PCP), a life-threatening disease in immunosuppressed patients.